Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 33
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Revascularization and outcomes in ischaemic left ventricular dysfunction after heart failure admission, The RevascHeart study

  • Moliner-Abós, Carles|||0000-0002-9264-5804
  • Calvo-Barceló, Maria
  • Solé González, Eduard|||0000-0002-5727-9925
  • Borrellas Martín, Andrea
  • Fluvià Brugués, Paula
  • Sánchez Vega, Jesús|||0000-0001-7250-8362
  • Tauron, Manel|||0000-0002-5864-519X
  • Tobías-Castillo, Pablo E.|||0000-0003-0304-6197
  • de la Fuente Mancera, Juan Carlos
  • Vilardell Rigau, Pau
  • Vila-Olives, Rosa|||0000-0002-2933-2020
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Arzamendi, Dabit|||0000-0001-7543-5867
  • Ferreira-Gonzalez, Ignacio|||0000-0002-1208-5561
  • Mirabet Pérez, Sonia|||0000-0001-5955-2748
Aims: Despite numerous trials on revascularization in patients with heart failure (HF) and ischaemic left ventricular (LV) dysfunction, its role remains unsettled. Guideline-directed medical therapy (GDMT) for HF has shown benefits on outcomes. This multicentre study aims to compare long-term mortality between revascularization and GDMT in patients with ischaemic LV dysfunction following admission for HF. Methods and results: Between 2012 and 2023, 408 patients admitted for HF with a LV ejection fraction (LVEF) of 40% or less and documented coronary artery disease (CAD) were included. Patients were categorized into two groups based on their initial treatment decision: revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG]) or GDMT. The primary outcome was rate of all-cause or cardiovascular mortality, and secondary outcomes included type of revascularization (PCI vs. CABG) and LV reverse remodelling. After a median 44.6-month follow-up, 100 patients (33%) died in the revascularization group, compared to 44 (43%) in the GDMT group. Multivariate analysis showed no significant benefit of revascularization on all-cause mortality (hazard ratio [HR] 0.81, 95% confidence interval [CI] 0.48-1.39, p = 0.45) or cardiovascular mortality (HR 0.97, 95% CI 0.62-1.52, p = 0.90) compared to GDMT. Neither CABG (HR 0.74, 95% CI 0.51-1.08, p = 0.13) nor PCI (HR 0.98, 95% CI 0.62-1.55, p = 0.93) demonstrated a mortality reduction compared to GDMT. Both groups experienced significant reductions in LV size and improvements in LVEF, greater in the revascularization group. Conclusion: Revascularization did not outperform GDMT in ischaemic LV dysfunction following HF admission in this retrospective analysis. Larger prospective studies are needed to clarify the potential role of revascularization in improving outcomes.
Repisalud
Publication Artículo científico (JournalArticle)

Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: a meta-analysis

  • Garcia-Alvarez, Monica
  • Jimenez-Sousa, Maria Angeles
  • Fernandez-Rodriguez, Amanda
  • Guzman-Fulgencio, Maria
  • Resino, Salvador
There is growing evidence that vitamin D is related to chronic hepatitis C (CHC) pathogenicity. We analyzed the relationship of vitamin D status with advanced liver fibrosis (ALF) in CHC treatment-naïve patients and sustained virologic response (SVR) in CHC patients on pegylated interferon alpha plus ribavirin (pegIFNα/ribavirin) therapy. We performed a meta-analysis of all eligible studies published to date (April, 2014) in PubMed, SCOPUS, LILACS, and the Cochrane Library, assessing plasma/serum vitamin D levels related to ALF and/or SVR. Pooled odds ratios (ORs) were estimated by either fixed or random effects models. Fourteen studies were selected from the literature search, seven for ALF (1,083 patients) and 11 for SVR (2,672 patients). For liver fibrosis, low vitamin D status was related to a diagnosis of ALF, with the cutoffs of 10 ng/mL (OR=2.37, 95% confidence interval [CI]=1.20, 4.72) and 30 ng/mL (OR=2.22, 95% CI=1.24, 3.97) being significant, and a near-significance for 20 ng/mL (OR=1.44, 95% CI=0.99, 2.12). Regarding SVR, a significant heterogeneity among studies was found (P<0.001), and we only found a significant association with SVR for a vitamin D cutoff of 20 ng/mL (OR=0.53, 95% CI=0.31, 0.91). When meta-analysis was performed excluding the outliers, significant pooled ORs were found for all patients (10 ng/mL [OR=0.48, 95% CI=0.34, 0.67] and 20 ng/mL [OR=0.58, 95% CI=0.45, 0.76]) and GT1/4 patients (10 ng/mL [OR=0.53, 95% CI=0.34, 0.81] and 20 ng/mL [OR=0.54, 95% CI=0.39, 0.74]). Conclusion: Low vitamin D status in CHC patients is associated with a higher likelihood of having ALF and lower odds of achieving SVR following pegIFNα/ribavirin therapy.
Repisalud
Publication Artículo científico (JournalArticle)

Mortality of patients infected with HIV in the intensive care unit (2005 through 2010): significant role of chronic hepatitis C and severe sepsis

  • Medrano, José
  • Álvaro-Meca, Alejandro
  • Boyer, Alexandre
  • Jimenez-Sousa, Maria Angeles
  • Resino, Salvador
INTRODUCTION: The combination antiretroviral therapy (cART) has led to decreased opportunistic infections and hospital admissions in human immunodeficiency virus (HIV)-infected patients, but the intensive care unit (ICU) admission rate remains constant (or even increased in some instances) during the cART era. Hepatitis C virus (HCV) infection is associated with an increased risk for hospital admission and/or mortality (particularly those related to severe liver disease) compared with the general population. The aim of this study was to assess the mortality among HIV-infected patients in ICU, and to evaluate the impact of HIV/HCV coinfection and severe sepsis on ICU mortality. METHODS: We carried out a retrospective study based on patients admitted to ICU who were recorded in the Minimum Basic Data Set (2005 through 2010) in Spain. HIV-infected patients (All-HIV-group (n = 1,891)) were divided into two groups: HIV-monoinfected patients (HIV group (n = 1,191)) and HIV/HCV-coinfected patients (HIV/HCV group (n = 700)). A control group (HIV(-)/HCV(-)) was also included (n = 7,496). RESULTS: All-HIV group had higher frequencies of severe sepsis (57.7% versus 39.4%; P < 0.001) than did the control group. Overall, ICU mortality in patients with severe sepsis was much more frequent than that in patients without severe sepsis (other causes) at days 30 and 90 in HIV-infected patients and the control group (P < 0.001). Moreover, the all-HIV group in the presence or absence of severe sepsis had a higher percentage of death than did the control group at days 7 (P < 0.001), 30 (P < 0.001) and 90 (P < 0.001). Besides, the HIV/HCV group had a higher percentage of death, both in patients with severe sepsis and in patients without severe sepsis compared with the HIV group at days 7 (P < 0.001) and 30 (P < 0.001), whereas no differences were found at day 90. In a bayesian competing-risk model, the HIV/HCV group had a higher mortality risk (adjusted hazard ratio (aHR) = 1.44 (95% CI = 1.30 to 1.59) and aHR = 1.57 (95% CI = 1.38 to 1.78) for patients with and without severe sepsis, respectively). CONCLUSIONS: HIV infection was related to a higher frequency of severe sepsis and death among patients admitted to the ICU. Besides, HIV/HCV coinfection contributed to an increased risk of death in both the presence and the absence of severe sepsis.
Repisalud
Publication Artículo científico (JournalArticle)

Genetic polymorphisms located in genes related to immune and inflammatory processes are associated with end-stage renal disease: a preliminary study

  • Jimenez-Sousa, Maria Angeles
  • López, Elisabeth
  • Fernandez-Rodriguez, Amanda
  • Tamayo, Eduardo
  • Fernandez-Navarro, Pablo L
  • Segura-Roda, Laura
  • Heredia, María
  • Gómez-Herreras, José I
  • Bustamante, Jesús
  • García-Gómez, Juan Miguel
  • Bermejo-Martin, Jesús F
  • Resino, Salvador
BACKGROUND: Chronic kidney disease progression has been linked to pro-inflammatory cytokines and markers of inflammation. These markers are also elevated in end-stage renal disease (ESRD), which constitutes a serious public health problem. OBJECTIVE: To investigate whether single nucleotide polymorphisms (SNPs) located in genes related to immune and inflammatory processes, could be associated with ESRD development. DESIGN AND METHODS: A retrospective case-control study was carried out on 276 patients with ESRD and 288 control subjects. Forty-eight SNPs were genotyped via SNPlex platform. Logistic regression was used to assess the relationship between each sigle polymorphism and the development of ESRD. RESULTS: Four polymorphisms showed association with ESRD: rs1801275 in the interleukin 4 receptor (IL4R) gene (OR: 0.66 (95%CI = 0.46-0.95); p = 0.025; overdominant model), rs4586 in chemokine (C-C motif) ligand 2 (CCL2) gene (OR: 0.70 (95%CI = 0.54-0.90); p = 0.005; additive model), rs301640 located in an intergenic binding site for signal transducer and activator of transcription 4 (STAT4) (OR: 1.82 (95%CI = 1.17-2.83); p = 0.006; additive model) and rs7830 in the nitric oxide synthase 3 (NOS3) gene (OR: 1.31 (95%CI = 1.01-1.71); p = 0.043; additive model). After adjusting for multiple testing, results lost significance. CONCLUSION: Our preliminary data suggest that four genetic polymorphisms located in genes related to inflammation and immune processes could help to predict the risk of developing ESRD.
Repisalud
Publication Artículo científico (JournalArticle)

Association between IL7R polymorphisms and severe liver disease in HIV/HCV coinfected patients: a cross-sectional study

  • Guzman-Fulgencio, Maria
  • Berenguer, Juan
  • Jimenez-Sousa, Maria Angeles
  • Pineda-Tenor, Daniel
  • Aldámiz-Echevarria, Teresa
  • Garcia-Broncano, Pilar
  • Carrero, Ana
  • Garcia-Alvarez, Monica
  • Tejerina, Francisco
  • Díez, Cristina
  • Vázquez-Morón, Sonia
  • Resino, Salvador
Background: Interleukin-7 (IL-7) is a critical factor for T cell development and for maintaining and restoring homeostasis of mature T cells. Polymorphisms at α-chain of the IL-7 receptor (IL7R or CD127) gene are related to evolution of HIV-infection, but there are no data concerning the evolution of hepatitis C virus (HCV) infection. The aim of this study was to analyze the association between IL7R polymorphisms and severe liver disease in HCV/HIV coinfected patients. Methods: We performed a cross-sectional study in 220 naïve patients who underwent a liver biopsy. IL7R polymorphisms (rs6897932, rs987106 and rs3194051) were genotyped using the GoldenGate(®) assay. The outcome variables were: (a) liver biopsy: advanced fibrosis (F ≥ 3), severe activity grade (A3); (b) non-invasive indexes: advanced fibrosis (APRI ≥1.5 and FIB-4 ≥3.25). Logistic regression analysis was used to investigate the association between IL7R polymorphisms and outcome variables. This test gives the differences between groups and the odds ratio (OR) for liver disease. Results: Patients with rs6897932 CC genotype had higher likelihood of having A3 than patients with rs6897932 CT/TT (adjusted odds ratio (aOR) = 4.16; p = 0.026). Patients with rs987106 TT genotype had higher odds of having F ≥ 3 (aOR = 3.09; p = 0.009) than rs987106 AA/AT carriers. Finally, patients with rs3194051 AA genotype had higher odds of having severe liver fibrosis (F ≥ 3; APRI ≥1.5, and FIB4 ≥3.25) than patients with rs3194051 AG/GG genotype [aOR = 2.73 (p = 0.010); aOR = 2.52 (p = 0.029); and aOR = 4.01 (p = 0.027); respectively]. The CTA haplotype (comprised of rs6897932, rs987106, and rs3194051) carriers had higher odds of having F ≥ 3 (aOR = 1.85; p = 0.012), APRI ≥1.5 (aOR = 1.94; p = 0.023), and FIB4 ≥3.25 (aOR = 2.47; p = 0.024). Conversely, the CAG haplotype carriers had lower odds of having F ≥ 3 (aOR = 0.48; p = 0.011), APRI ≥1.5 (aOR = 0.48; p = 0.029), and FIB4 ≥3.25 (aOR = 0.29; p = 0.010). Conclusions: The presence of IL7R polymorphisms seems to be related to severe liver disease in HIV/HCV coinfected patients, because patients with unfavorable IL7R genotypes (rs6897932 CC, rs987106 TT, and rs3194051AA) had a worse prognosis of CHC.
Repisalud
Publication Artículo científico (JournalArticle)

Fifteen-Year Trends in the Prevalence of Diabetes among Hospitalized HIV-Infected Patients in Spain (1997-2012)

  • Álvaro-Meca, Alejandro
  • Jiménez-García, Rodrigo
  • Jimenez-Trujillo, Isabel
  • Hernandez-Barrera, Valentin
  • de Miguel-Diez, Javier
  • Resino, Salvador
  • Lopez-de-Andres, Ana
OBJECTIVE: To describe trends in the prevalence of diabetes among hospitalized HIV-infected patients between 1997 and 2012 in Spain and compare them with those of age- and sex-matched non-HIV-infected patients. METHODS: The study was based on Spanish national hospital discharge data. We performed a retrospective study for the period 1997-2012. HIV infection (HIV-infected versus non-HIV-infected [control group])and calendar period in relation to widespread use of combination antiretroviral therapy (cART) (1997-1999; 2000-2003; 2004-2007 and 2008-2012), were the exposure variables The outcome variables were diagnosis of diabetes and in-hospital mortality (IHM). RESULTS: From 1997 to 2012, we identified 91,752 cases of diabetes: 15,398 in the HIV-infected group (403,277 hospital admissions) and 76,354 in the non-HIV-infected group (1,503,467 hospital admissions). Overall, HIV-infected patients had lower prevalence values for diabetes than non-HIV-infected patients throughout the follow-up (3.8% vs. 5.1%; p<0.001). The prevalence of diabetes increased 1.56-fold among non-HIV-infected patients and 4.2-fold among HIV-infected patients. The prevalence of diabetes in females was almost twice as high in HIV-infected patients as in non-HIV-infected patients during the last study period (4.72% vs. 2.88%; p<0.001). Diabetes showed a protective effect against IHM throughout the study period (aOR = 0.70; 95%CI, 0.65-0.75). CONCLUSIONS: During the cART era, the prevalence of diabetes has increased sharply among HIV-infected hospitalized patients compared with matched non-HIV-infected subjects. The prevalence of diabetes is rising very fast among HIV-infected women. Diabetes has a protective effect on IHM among HIV-infected patients. Nevertheless, our study has several limitations. No information is available in the database used on important sociodemographic characteristics and relevant clinical variables including duration of the HIV infection, treatments used, drug resistance, treatment adherence or CD4 count, among others. Also, it is possible that increase of diabetes prevalence could reflect the improvement in recording habits.
Repisalud
Publication Artículo científico (JournalArticle)

PPARγ2 Pro12Ala polymorphism was associated with favorable cardiometabolic risk profile in HIV/HCV coinfected patients: a cross-sectional study

  • Trento, Alfonsina
  • Fernandez-Rodriguez, Amanda
  • Pineda-Tenor, Daniel
  • Jimenez-Sousa, Maria Angeles
  • Garcia-Alvarez, Monica
  • Resino, Salvador
  • Berenguer, Juan
  • Miralles, Pilar
  • Aldámiz-Echevarria, Teresa
  • López, Juan Carlos
  • Micheloud, Dariela
Background: Peroxisome proliferator-activated receptor gamma-2 gene (PPARγ2) rs1801282 (Pro12Ala) polymorphism has been associated with lower risk of metabolic disturbance and atherosclerosis. The aim of this study was to analyze the association between the Pro12Ala polymorphism and cardiometabolic risk factors in human immunodeficiency virus (HIV)/Hepatitis C virus (HCV)-coinfected patients. Methods: We carried out a cross-sectional study on 257 HIV/HCV coinfected patients. PPARγ2 polymorphism was genotyped by GoldenGate® assay. The main outcome measures were: i) serum lipids (cholesterol, triglycerides, high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C), LDL-C/HDL-C, and atherogenic index (AI)); ii) homeostatic model assessment (HOMA-IR) values; iii) serum adipokines (leptin, adiponectin, resistin, plasminogen activator inhibitor-1(PAI-1), hepatic growth factor (HGF), and nerve growth factor (NGF)). Generalized Linear Models (GLM) with gamma distribution (log-link) were used to investigate the association between PPARγ2 polymorphism and continuous outcome variables. This test gives the differences between groups and the arithmetic mean ratio (AMR) in continuous outcome variables between groups. Results: The rs1801282 CG/GG genotype was associated with low values of cholesterol (adjusted arithmetic mean ratio (aAMR) = 0.87 (95% of confidence interval (95% CI) = 0.79; 0.96); p = 0.004) and LDL-C (aAMR = 0.79 (95% CI = 0.68; 0.93); p = 0.004). Furthermore, rs1801282 CG/GG was associated with low values of HOMA-IR (aAMR = 0.69 (95% CI = 0.49; 0.98); p = 0.038) among patients with significant liver fibrosis (F ≥ 2). Moreover, rs1801282 CG/GG was also associated with low serum values of hepatic growth factor (HGF) (aAMR = 0.61 (95% CI = 0.39; 0.94); p = 0.028), and nerve growth factor (NGF) (aAMR = 0.47 (95% CI = 0.26; 0.84); p = 0.010). The serum levels of leptin, adiponectin, resistin, and PAI-1 did not show significant differences. Conclusions: The presence of PPARγ2 rs1801282 G allele (Ala variant) was associated with a protective cardiometabolic risk profile versus CC genotype in HIV/HCV-coinfected patients. Thus, PPARγ2 rs1801282 polymorphism may play a significant role in the development of metabolic disorders in HIV/HCV coinfected patients, and might have an influence on the cardiovascular risk.
Repisalud
Publication Artículo científico (JournalArticle)

Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis

  • Pineda-Tenor, Daniel
  • Jimenez-Sousa, Maria Angeles
  • Resino, Salvador
  • Garcia-Alvarez, Monica
  • Vázquez-Morón, Sonia
Background: There is growing evidence that variations in the gene encoding inosine triphosphate pyrophosphohydrolase (ITPase), known as inosine triphosphatase (ITPA), are related to hemolytic anemia, which is frequently observed among hepatitis C virus (HCV)-infected patients receiving ribavirin (RBV)-based therapy. We performed a meta-analysis of all eligible studies assessing ITPA gene polymorphisms related to RBV-induced hemolytic anemia in HCV-infected patients published in PubMed, Embase and the Cochrane library prior to the end of 2014. Methods: Three outcomes were evaluated: (1) hemoglobin decline, (2) severe anemia, and (3) RBV dose reduction or treatment discontinuation. Pooled odds ratio (OR) and 95 % confidence interval (95 % CI) were estimated by either fixed or random effects models. Results: Twenty-nine studies were selected from the literature search: 20 references involving 6533 individuals for hemoglobin decline, 13 references on 3764 patients for severe anemia, and 16 references on 3918 patients for RBV dose reduction or discontinuation. Significant associations with hemoglobin decline were found for rs1127354 CC [OR = 12.84 (95 % CI 7.44; 22.17)], rs7270101 AA [OR = 3.41 (95 % CI 2.08; 5.59)] and rs6051702 AA [OR = 4.43 (95 % CI 2.80; 7.00)] genotypes. Moreover, significant associations with hemoglobin decline were also found for absent [OR = 6.01 (95 % CI 4.84; 7.46)] and mild [OR = 4.68 (95 % CI 2.83; 7.74)] ITPase deficiency haplotypes. The ITPA rs1127354 CC genotype and absent ITPase deficiency haplotype were also associated with severe anemia {[OR = 7.77 (95 % CI 5.03; 12.00)] and [OR = 4.79 (95 % CI 1.69; 13.56)], respectively}. Additionally, the rs1127354 CC genotype showed significant association with RBV dose reduction or stopping treatment (OR = 2.24; 95 % CI 1.79; 2.81). Conclusions: ITPA polymorphisms increase the likelihood of developing hemolytic anemia for HCV-infected patients on RBV-based therapy, particularly rs1127354 CC and rs7270101 AA genotypes, suggesting the utility of screening for ITPA polymorphisms to avoid hematological toxicity and increase adherence to RBV-based therapy.
Repisalud
Publication Artículo científico (JournalArticle)

Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C

  • Jimenez-Sousa, Maria Angeles
  • Fernandez-Rodriguez, Amanda
  • Guzman-Fulgencio, Maria
  • Garcia-Alvarez, Monica
  • Resino, Salvador
BACKGROUND: Since 2009, several studies have identified single-nucleotide polymorphisms (SNPs) near the gene encoding for interleukin (IL)-28 (IL28B) that are strongly associated with spontaneous and treatment-induced hepatitis C virus (HCV) clearance. Because this large amount of data includes some inconsistencies, we consider assessment of the global estimate for each SNP to be essential. METHODS: Relevant studies assessing IL28B polymorphisms associated with sustained virologic response (SVR) and spontaneous clearance (SC) were identified from a literature search of PubMed up to 9 July, 2012. Studies were eligible studies if they included patients infected with HCV or HCV/HIV, or assessed any SNP located within or near the IL28B gene, SVR data available under standard treatment, and/or SC data in patients with acute HCV infection. Pooled odds ratios were estimated by fixed or random effects models when appropriate. Variables such as HCV genotype, ethnicity, and type of co-infection were studied. RESULTS: Of 282 screened studies, 67 were selected for SVR and 10 for SC. In total, 20,163 patients were studied for SVR and 3,554 for SC. For SVR, we found that all SNPs showed strong associations in patients with HCV genotypes 1 and 4, whereas the pooled ORs were almost three times lower for genotypes 2 and 3 (rs12979860 and rs8099917). Regarding ethnicity, the SNP most associated with SVR was rs12979860 in white patients, whereas in East Asians it seemed to be rs8099917. The most studied SNP (rs12979860) showed similar results for patients co-infected with HCV/HIV, as for those infected with HCV only. Finally, rs12979860 and rs8099917 both appeared to be associated with SC. CONCLUSIONS: IL28B polymorphisms influence both the outcome of interferon treatment and the natural clearance of HCV. However we did not identify a universal predictor SNP, as the best genetic markers differed depending on patient ethnicity, genotype, and type of infection. Nevertheless, our results may be useful for more precise treatment decision-making.
Repisalud
Publication Artículo científico (JournalArticle)

Impact of chronic hepatitis C on mortality in cirrhotic patients admitted to intensive-care unit

  • Álvaro-Meca, Alejandro
  • Jimenez-Sousa, Maria Angeles
  • Boyer, Alexandre
  • Medrano, José
  • Reulen, Holger
  • Kneib, Thomas
  • Resino, Salvador
BACKGROUND: Cirrhosis and severe sepsis are factors associated with increased mortality in intensive care unit (ICU), but chronic hepatitis C (CHC) has been less studied in ICU. The aim of this study was to analyze the impact of CHC on the mortality of cirrhotic patients admitted to ICU according to severe sepsis and decompensated cirrhosis. METHODS: We carried out a retrospective study based on CHC-cirrhotic patients (CHC-group) admitted to ICU (n = 1138) and recorded in the Spanish Minimum Basic Data Set (2005-2010). A control-group (randomly selected cirrhotic patients without HIV, HBV, or HCV infections) was also included (n = 4127). The primary outcome variable was ICU mortality. The cumulative mortality rate on days 7, 30, and 90 in patients admitted to the ICUs was calculated by dividing the number of deaths by the number of patients admitted to the ICU. The adjusted hazard ratio (aHR) for death in the ICU was estimated through a semi-parametric Bayesian model of competing risk. RESULTS: The CHC-group had a higher cumulative incidence of severe sepsis than the control-group in compensated cirrhosis (37.4 vs. 31.1%; p = 0.024), but no differences between the CHC-group and the control-group in decompensated cirrhosis were found. Moreover, a higher cumulative incidence of severe sepsis was associated with decompensated cirrhosis compared to compensated cirrhosis in the control-group (40.1 vs. 31.1%; p < 0.001) whereas this was not observed in the CHC group (38.1 vs. 37.4%; p = 0.872). The CHC-group had higher cumulative mortality than the control-group by days 7 (47 vs. 41.3%; p < 0.001), 30 (78.5 vs. 73.5%; p < 0.001), and 90 (96.3 vs. 95.9%; p < 0.001). In a competitive risk model, the CHC-group had a higher risk of dying if the ICU course was complicated by severe sepsis (adjusted hazard ratio (aHR) = 1.19; p = 0.003), but no significant values in patients with absence of severe sepsis were found (aHR = 1.09; p= 0.068). When patients were stratified by cirrhosis stage and severe sepsis, CHC patients with compensated cirrhosis had the higher risk of death if they had severe sepsis (aHR = 1.35; p = 0.002). Moreover, the survival was low in patients with decompensated cirrhosis and severe sepsis but we did not find significant differences between CHC-group and control-group. CONCLUSIONS: CHC was associated with an increased risk of death in cirrhotic patients admitted to ICUs, particularly in patients with compensated cirrhosis and severe sepsis.
Repisalud
Publication Artículo científico (JournalArticle)

Toll-like receptor 8 (TLR8) polymorphisms are associated with non-progression of chronic hepatitis C in HIV/HCV coinfected patients

  • Fernandez-Rodriguez, Amanda
  • Berenguer, Juan
  • Jimenez-Sousa, Maria Angeles
  • Garcia-Alvarez, Monica
  • Aldámiz-Echevarria, Teresa
  • Pineda-Tenor, Daniel
  • Díez, Cristina
  • De la Barrera, Jorge
  • Bellón, José María
  • Briz, Veronica
  • Resino, Salvador
Toll-like receptor 8 (TLR8) polymorphisms have been related to hepatitis C virus (HCV) infection. The aim was to estimate the association of TLR8 polymorphisms with HCV-related outcomes in HIV/HCV coinfected patients. We performed a cross-sectional study of 220 patients who underwent a liver biopsy. TLR8 polymorphisms were genotyped using GoldenGate® assay. The outcome variables were non-fibrosis (F0), mild-inflammation (A0/A1), and non-steatosis [fatty hepatocytes (FH) <10%]. Logistic regression analysis was used to compare the outcome variables according to TLR8 polymorphisms. Four polymorphisms were analyzed (rs1013151, rs5744069, rs17256081 and rs3764880rs1013151). Female patients had higher frequency of TLR8 major alleles at rs17256081 and rs101315, and minor alleles at rs3764880 and rs5744069. Male patients had higher frequency of TLR8 minor alleles except for rs3764880, where major alleles were higher (p<0.01). Two TLR8 polymorphisms (rs1013151 and rs5744069) were significantly associated with non-fibrosis (F0) [adjusted odds ratio (aOR)=4.42 (95% of confidence interval (95%CI)=1.54; 12.68) (p=0.006) and aOR=4.76 (95%CI=1.69; 13.37) (p=0.003); respectively]. When data were stratified by gender, rs1013151 and rs5744069 polymorphisms remained significant for male patients [adjusted odds ratio (aOR)=4.49 (95%CI=1.08; 18.62) (p=0.039) and aOR=6.17 (95%CI=1.45; 26.20) (p=0.014); respectively]. When data were stratified by major HCV genotypes, patients infected with HCV genotype 1 (GT1) had significant values for both rs1013151 and rs5744069 polymorphisms [aOR=5.79 (95%CI=1.44; 23.32) (p=0.013) and aOR=8.01 (95%CI=2.16; 35.65) (p=0.005); respectively]. Finally, none of the TLR8 polymorphisms were significantly associated with mild-inflammation or non-steatosis. In conclusion, TLR8 polymorphisms seem to be related to non-progression of liver fibrosis in HIV/HCV coinfected patients, particularly in males and those patients infected with GT1.
Repisalud
Publication Artículo científico (JournalArticle)

Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients

  • Medrano, Luz Maria
  • Jimenez-Sousa, Maria Angeles
  • Fernandez-Rodriguez, Amanda
  • Martinez, Isidoro
  • Rallón, Norma
  • Berenguer, Juan
  • Resino, Salvador
  • Soriano, Vicente
  • Aldámiz-Echevarria, Teresa
  • García, Marcial
  • Tejerina, Francisco
  • Benito, José Miguel
BACKGROUND AND AIMS: TRIM5 and TRIM22 are restriction factors involved in innate immune response and exhibit anti-viral activity. Single nucleotide polymorphisms (SNPs) at TRIM5 and TRIM22 genes have shown to influence several viral infections such as human immunodeficiency virus (HIV), hepatitis B, as well as measles and rubella vaccination. The aim of this study is to analyze whether TRIM5 and TRIM22 polymorphisms are associated with liver fibrosis inflammation-related biomarkers and response to pegylated-interferon-alpha plus ribavirin (pegIFNα/RBV) therapy in HIV/hepatitis C virus (HCV) coinfected patients. METHODS: A retrospective study was performed in 319 patients who started pegIFNα/RBV therapy. Liver fibrosis stage was characterized in 288 patients. TRIM5 rs3824949 and TRIM22 polymorphisms (rs1063303, rs7935564, and rs7113258) were genotyped using the GoldenGate assay. The primary outcomes were: a) significant liver fibrosis (≥F2) evaluated by liver biopsy or transient elastography (liver stiffness values ≥7.1 Kpa); b) sustained virological response (SVR) defined as no detectable HCV viral load (<10 IU/mL) at week 24 after the end of the treatment. The secondary outcome variable was plasma chemokine levels. RESULTS: Patients with TRIM5 rs3824949 GG genotype had higher SVR rate than patients with TRIM5 rs3824949 CC/CG genotypes (p = 0.013), and they had increased odds of achieving SVR (adjusted odds ratio (aOR = 2.58; p = 0.012). Patients with TRIM22 rs1063303 GG genotype had higher proportion of significant liver fibrosis than patients with rs1063303 CC/CG genotypes (p = 0.021), and they had increased odds of having significant hepatic fibrosis (aOR = 2.19; p = 0.034). Patients with TRIM22 rs7113258 AT/AA genotype had higher SVR rate than patients with rs7113258 TT genotypes (p = 0.013), and they had increased odds of achieving SVR (aOR = 1.88; p = 0.041). The TRIM22 haplotype conformed by rs1063303_C and rs7113258_A was more frequent in patients with SVR (p = 0.018) and was significantly associated with achieving SVR (aOR = 2.80; p = 0.013). The TRIM5 rs3824949 GG genotype was significantly associated with higher levels of GRO-α (adjusted arithmetic mean ratio ((aAMR) = 1.40; p = 0.011) and MCP-1 (aAMR = 1.61; p = 0.003). CONCLUSIONS: TRIM5 and TRIM22 SNPs are associated to increased odds of significant liver fibrosis and SVR after pegIFNα/RBV therapy in HIV/HCV coinfected patients. Besides, TRIM5 SNP was associated to higher baseline levels of circulating biomarkers GRO and MCP-1.
Repisalud
Publication Artículo científico (JournalArticle)

Rate of candidiasis among HIV-infected children in Spain in the era of highly active antiretroviral therapy (1997-2008)

  • Álvaro-Meca, Alejandro
  • Jensen, Julia
  • Micheloud, Dariela
  • Diaz Franco, Asuncion
  • Gurbindo, Dolores
  • Resino, Salvador
BACKGROUND: Candidiasis is the most common opportunistic infection seen in human immunodeficiency virus (HIV)-infected individuals. The aim of our study was to estimate the candidiasis rate and evaluate its trend in HIV-infected children in Spain during the era of highly active antiretroviral therapy (HAART) compared to HIV-uninfected children. METHODS: We carried out a retrospective study. Data were obtained from the records of the Minimum Basic Data Set from hospitals in Spain. All HIV-infected children were under 17 years of age, and a group of HIV-uninfected children with hospital admissions matching the study group by gender and age were randomly selected. The follow-up period (1997-2008) was divided into three calendar periods: a) From 1997 to 1999 for early-period HAART; b) from 2000 to 2002 for mid-period HAART; and c) from 2003 to 2008 for late-period HAART. RESULTS: Among children with hospital admissions, HIV-infected children had much higher values than HIV-uninfected children during each of the three calendar periods for overall candidiasis rates (150.0 versus 6.1 events per 1,000 child hospital admissions/year (p < 0.001), 90.3 versus 3.1 (p < 0.001), and 79.3 versus 10.7 (p < 0.001), respectively) and for non-invasive Candida mycosis (ICM) rates (118.5 versus 3.8 (p < 0.001), 85.3 versus 2.3 (p < 0.001), and 80.6 versus 6.0 (p < 0.001), respectively). In addition, HIV-infected children also had higher values of ICM rates than HIV-uninfected children, except during the last calendar period when no significant difference was found (32.4 versus 1.2 (p < 0.001), 11.6 versus 0.4 (p < 0.001), and 4.6 versus 2.3 (p = 0.387), respectively). For all children living with HIV/AIDS, the overall candidiasis rate (events per 1,000 HIV-infected children/year) decreased from 1997-1999 to 2000-2002 (18.8 to 10.6; p < 0.001) and from 2000-2002 to 2003-2008 (10.6 to 5.7; p = 0.060). Within each category of candidiasis, both non-ICM and ICM rates experienced significant decreases from 1997-1999 to 2003-2008 (15.9 to 5.7 (p < 0.001) and 4.1 to 0.3 (p < 0.001), respectively). CONCLUSIONS: Although the candidiasis rate still remains higher than in the general population (from 1997 to 2008), candidiasis diagnoses have decreased among HIV-infected children throughout the HAART era, and it has ceased to be a major health problem among children with HIV infection.
Repisalud
Publication Artículo científico (JournalArticle)

Trend of pneumonia incidence among children infected with HIV in the era of highly active antiretroviral therapy.

  • Micheloud, Dariela
  • Álvaro-Meca, Alejandro
  • Jensen, Julia
  • Diaz Franco, Asuncion
  • Resino, Salvador
We performed a retrospective study using a cross-sectional design for each year from 1997 to 2008 to evaluate the trend in pneumonia rates among HIV-infected children in the highly active antiretroviral therapy (HAART) era in Spain. We found that rate of pneumonia decreased among HIV-Infected children in the highly active antiretroviral therapy era but still remained higher than in the general population. Non-AIDS-defining pneumonia remains a significant health problem for HIV-infected children.
Repisalud
Publication Artículo científico (JournalArticle)

FTOrs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients

  • Pineda-Tenor, Daniel
  • Berenguer, Juan
  • Jimenez-Sousa, Maria Angeles
  • Garcia-Alvarez, Monica
  • Aldámiz-Echevarria, Teresa
  • Carrero, Ana
  • Vázquez-Morón, Sonia
  • Garcia-Broncano, Pilar
  • Díez, Cristina
  • Tejerina, Francisco
  • Guzman-Fulgencio, Maria
  • Resino, Salvador
Background: The Fat Mass and Obesity-Associated Protein (FTO) gene rs9939609 single nucleotide polymorphism (SNP) has been associated with obesity, metabolic syndrome, insulin resistance (IR), and type 2 diabetes mellitus in the general population. The aim of our study was to examine for the first time the association of the rs9939609 polymorphism with metabolic disturbances, liver disease and virologic response to hepatitis C virus (HCV) therapy with pegylated-interferon-alpha plus ribavirin (pegIFNα/RBV) in human immunodeficiency virus (HIV)/HCV coinfected patients. Methods: We carried out a cross-sectional study in 261 patients, of whom 178 were subsequently treated with pegIFNα/RBV therapy. FTO rs9939609 and IFNL3 rs12980275 polymorphisms were genotyped by GoldenGate®. The main outcomes were: 1) metabolic disturbances: insulin resistance (homeostatic model assessment (HOMA-IR)) and overweight (body mass index (BMI)); 2) liver disease (Metavir score): significant fibrosis (F ≥2) and steatosis (>10% fatty hepatocytes); and 3) virologic response to HCV treatment: sustained virologic response (SVR). Results: The rs9939609 AA genotype was associated with higher values of BMI (adjusted arithmetic mean ratio (aAMR) = 1.08; 95% confidence interval (95%CI) = 1.03 to 1.14; P = 0.002) and HOMA-IR (aAMR = 1.32; 95%CI = 1.03 to 1.69; P = 0.027). Patients with an rs9939609 AA genotype had higher likelihoods of achieving values of BMI ≥27.5 kg/m2 (adjusted odds ratio (aOR) = 3.46; 95%CI =1.17 to 10.21; P = 0.024), HOMA-IR ≥2.5 (aOR = 2.09; 95%CI = 1.02 to 4.32; P = 0.045), significant fibrosis (aOR = 2.34; 95%CI =1.02 to 5.36; P = 0.045) and steatosis (aOR = 3.65; 95%CI = 1.29 to 10.36; P = 0.015). The rs9939609 AT/AA genotype decreased the likelihood of achieving SVR (aOR = 0.58; 95%CI = 0.34 to 0.99; P = 0.044). A decision tree was performed with the genotypes of HCV, IFNL3 and FTO. The incorporation of rs9939609 significantly improves the prediction of SVR (P <0.05). The overall accuracy was 68.2%. Conclusions: Patients carrying the unfavourable AT/AA genotype of rs9939609 polymorphism had higher odds of metabolic disturbances and a lower likelihood of achieving successful virologic response to HCV therapy.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Contribución de congreso (ConferenceOutput)

Raw Earth Construction and Restoration Technique: Experimental Protocol and Interventions in the Historic Village of Al Jazeera Al Hamra (United Arab Emirates)

  • Liberotti, Riccardo
  • Amer, Valeria
  • Gusella, Vittorio
[EN] The evolving relationship between contemporary practice and inherited structures necessitates sustainablestrategies for the preservation and reinforcement of heritage assets, safeguarding their functionality overtime. This study investigates the mechanical properties of traditional and innovative mortar-basedmaterials for the repair of architectural elements, with a particular focus on artistic stuccoes anddecorative features. The research aims to reduce their vulnerability to environmental, seismic, andanthropogenic factors, including pollution and climate change, which accelerate material degradationand ageing. The mix designs of artificial stone materials appropriate for the proposed strategies make useof natural rocks (e.g., limestone, alabastrine gypsum) and different constituents (e.g., vegetable sisalfibres, siliceous/siliceous-aluminous pozzolana); innovative raw earth-based mortars are also studied forplastering, rendering and repair of earthen buildings. In particular, a minimum of three specimens foreach mix design will be tested through flexural mechanical tests in an undergoing phase of the researchand using a displacement-controlled testing machine, following a standardised protocol –scientificallyrecognised at an European level– specifically developed for mortars (elements that exhibit material affinitywith the interventions addressed in this study). The results will then be comparatively assessed,considering not only the structural performance but also the material compatibility for potential fieldapplications. Finally, with reference to a case study, a design approach is presented allowing forinterventions on existing structures and the creation of new architectural shapes in an intimate, seamlessdialogue: emblematic –following the example of San Francesco di Assisi– of an essentiality able ofcommunicate with clarity and power., The research was partially supported by the projects “Centro Internazionale per la ricerca sulle Scienze e Tecniche della Ricostruzione fisica, economica e sociale–STRIC”, Project FISR 2019: “Eco Earth” (code 00245) and the PRIN 2022 project “Composite and Bio-Inspired material Design for Engineering Applications” COB IDEA (code 2022MF4JR). This work has been funded by the European Union– NextGenerationEU under the Italian Ministry of University and Research (MUR) National Innovation Ecosystem grant ECS00000041 VITALITY CUP J97G22000170005.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Genetic polymorphisms located in genes related to immune and inflammatory processes are associated with end-stage renal disease: a preliminary study

  • Jimenez-Sousa, Mª Angeles
  • López, Elisabeth
  • Fernandez-Rodriguez, Amanda
  • Tamayo, Eduardo
  • Fernández-Navarro, Pablo
  • Segura Roda, Laura
  • Heredia, Maria
  • Gómez-Herreras, José I.
  • Bustamante, Jesus
  • Bermejo-Martin, Jesus F.
  • Garcia-Gomez, Juan M
  • Resino, Salvador
Background Chronic kidney disease progression has been linked to pro-inflammatory cytokines and markers of inflammation. These markers are also elevated in end-stage renal disease (ESRD), which constitutes a serious public health problem. Objective To investigate whether single nucleotide polymorphisms (SNPs) located in genes related to immune and inflammatory processes, could be associated with ESRD development. Design and methods A retrospective case-control study was carried out on 276 patients with ESRD and 288 control subjects. Forty-eight SNPs were genotyped via SNPlex platform. Logistic regression was used to assess the relationship between each sigle polymorphism and the development of ESRD. Results Four polymorphisms showed association with ESRD: rs1801275 in the interleukin 4 receptor (IL4R) gene (OR: 0.66 (95%CI=0.46-0.95); p=0.025; overdominant model), rs4586 in chemokine (C-C motif) ligand 2 (CCL2) gene (OR: 0.70 (95%CI=0.54-0.90); p=0.005; additive model), rs301640 located in an intergenic binding site for signal transducer and activator of transcription 4 (STAT4) (OR: 1.82 (95%CI=1.17-2.83); p=0.006; additive model) and rs7830 in the nitric oxide synthase 3 (NOS3) gene (OR: 1.31 (95%CI=1.01-1.71); p=0.043; additive model). After adjusting for multiple testing, results lost significance. Conclusion Our preliminary data suggest that four genetic polymorphisms located in genes related to inflammation and immune processes could help to predict the risk of developing ESRD., This work was supported by grants from Instituto de Salud Carlos III (Ref: PI08/0738 and PI11/00245) to SR and Junta de Castilla y Leon (Ref: GRS 234/A/08) to ET. MAJS is supported by a grant from Instituto de Salud Carlos III (CM10/00105).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Conductive polycaprolactone/gelatin/polyaniline nanofibres as functional scaffolds for cardiac tissue regeneration

  • Gil-Castell, O.
  • Ontoria-Oviedo, I.
  • Badia, J.D.
  • Sepúlveda, P.
  • Amaro-Prellezo, Elena
  • Ribes-Greus, A.|||0000-0003-2460-8291
[EN] The endorsement of functional features such as biocompatibility, mechanical integrity, or electrical conductivity to tissue engineering (TE) scaffolds is essential to stimulate cell adhesion and proliferation. In this study, electrospun nanofibers based on polycaprolactone (PCL) and gelatin (Ge) (ratios 60/40, 50/50, and 40/60), and polyaniline (PAni) particles (0.25, 0.50, and 1.00 %wt) were prepared. The time of dissolution in an acid solvent mixture before electrospinning allowed for obtaining nanofibers with controlled features. Changes in the molar mass (Mn from 90·103 to 15·103 g·mol-1), in the crystalline microstructure (Xc from 60 to 25%) and the surface morphology (diameter from 250 to 50 nm) due to the controlled hydrolytic action on PCL were found. In vitro degradability and biocompatibility were favoured as the dissolution time and gelatin percentage increased. The presence of PAni was revealed as non-cytotoxic and promoted a controlled increase of the electrical conductivity, that contributed to in vitro cardiomyocyte proliferation. Cellular centres in the vicinities of PAni microparticles could be identified in the scaffold with the 40/60 PCL/Ge scaffold with PAni (1.00 %wt), keeping the macrophages profile unaltered, which may determine the satisfactory resolution of cardiac injury and point out these scaffolds as appropriate candidates for cardiac TE., Generalitat Valenciana is thanked for the post-doctoral contracts of O. Gil-Castell (APOSTD/2020/155) and I. Ontoria-Oviedo (CDPT-01/20-A). The ISCIII is acknowledged for the RETICS Program (RD16/0011/0004) as well as for the grant PI19/00245, co-funded by the European Regional Development Fund-ERDF. Dr. M. Orzaez is recognised for kindly providing the THP-1 Cells (Centro de Investigaci ' on Principe Felipe, Valencia, Spain). Finally, the authors recognise the microscopy and cell cultures core facilities of UPV and IIS La Fe for their grateful collaboration.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Extracellular vesicles from dental pulp mesenchymal stem cells modulate macrophage phenotype during acute and chronic cardiac inflammation in athymic nude rats with myocardial infarction

  • Amaro-Prellezo, Elena
  • Tarazona, Sonia|||0000-0001-5346-1407
  • Gómez-Ferrer, Marta
  • Hakobyan, Lusine
  • Ontoria-Oviedo, Imelda
  • Peiró-Molina, Esteban
  • Salguero, Pedro
  • Ruiz-Saurí, Amparo
  • Selva-Roldán, Marta
  • Vives-Sanchez, Rosa
  • Sepúlveda, Pilar
[EN] Background/aims Extracellular vesicles (EVs) derived from dental pulp mesenchymal stem cells (DP-MSCs) are a promising therapeutic option for the treatment of myocardial ischemia. The aim of this study is to determine whether MSC-EVs could promote a pro-resolving environment in the heart by modulating macrophage populations.Methods EVs derived from three independent biopsies of DP-MSCs (MSC-EVs) were isolated by tangential flow-filtration and size exclusion chromatography and were characterized by omics analyses. Biological processes associated with these molecules were analyzed using String and GeneCodis platforms. The immunomodulatory capacity of MSC-EVs to polarize macrophages towards a pro-resolving or M2-like phenotype was assessed by evaluating surface markers, cytokine production, and efferocytosis. The therapeutic potential of MSC-EVs was evaluated in an acute myocardial infarction (AMI) model in nude rats. Infarct size and the distribution of macrophage populations in the infarct area were evaluated 7 and 21 days after intramyocardial injection of MSC-EVs.Results Lipidomic, proteomic, and miRNA-seq analysis of MSC-EVs revealed their association with biological processes involved in tissue regeneration and regulation of the immune system, among others. MSC-EVs promoted the differentiation of pro-inflammatory macrophages towards a pro-resolving phenotype, as evidenced by increased expression of M2 markers and decreased secretion of pro-inflammatory cytokines. Administration of MSC-EVs in rats with AMI limited the extent of the infarcted area at 7 and 21 days post-infarction. MSC-EV treatment also reduced the number of pro-inflammatory macrophages within the infarct area, promoting the resolution of inflammation.Conclusion EVs derived from DP-MSCs exhibited similar characteristics at the omics level irrespective of the biopsy from which they were derived. All MSC-EVs exerted effective pro-resolving responses in a rat model of AMI, indicating their potential as therapeutic agents for the treatment of inflammation associated with AMI., This work was supported in part by grants from the Instituto de Salud Carlos III PI19/00245, PI22/00230, and the RETICS Program (RD16/0011/0004), co-funded by FEDER "una manera de hacer Europa," from Agencia Valenciana de Innovacion (INNVA1/2021/29) and from SECAVEX project (AP2022-11 VLC-BIOMED programme). It was also supported by a Margarita Salas fellowship from Ministry of Universities-University of Valencia (MS21-119) and predoc-toral fellowships ACIF/2020/352 and ACIF/2018/254 from the Conselleria de Innovacion, Universidades, Ciencia y Sociedad Digital, and co-financed by the European Union through the Operational Program of the European Regional Development Fund (FEDER) of the Valencian Community 2014-2020.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Topical Administration of a Marine Oil Rich in Pro-Resolving Lipid Mediators Accelerates Wound Healing in Diabetic db/db Mice through Angiogenesis and Macrophage Polarization

  • Amaro-Prellezo, Elena
  • Ontoria-Oviedo, Imelda
  • Castellano, Delia
  • Venegas-Venegas, Elena
  • González-Santos, Fernando
  • Ruiz-Saurí, Amparo
  • Pelacho, Beatriz
  • Prósper, Felipe
  • Pérez del Caz, María Dolores
  • Sepúlveda, Pilar
[EN] Impaired wound healing in patients with type 2 diabetes (DM2) is characterized by chronic inflammation, which delays wound closure. Specialized pro-resolving lipid mediators (SPMs) are bioactive molecules produced from essential polyunsaturated fatty acids (PUFAs), principally omega-3 docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). SPMs are potent regulators of inflammation and have been used to suppress chronic inflammation in peripheral artery disease, non-alcoholic fatty liver disease, and central nervous system syndromes. LIPINOVA® is a commercially available safe-grade nutritional supplement made from a fractionated marine lipid concentrate derived from anchovy and sardine oil that is rich in SPMs and EPA, as well as DHA precursors. Here, we assessed the effect of LIPINOVA® in wound dressing applications. LIPINOVA® showed biocompatibility with keratinocytes and fibroblasts, reduced the abundance of pro-inflammatory macrophages (M¿1), and promoted in vitro wound closure. Daily application of the marine oil to open wounds made by punch biopsy in db/db mice promoted wound closure by accelerating the resolution of inflammation, inducing neoangiogenesis and M¿1/M¿2 macrophage polarization. In conclusion, LIPINOVA® displays pro-resolutive properties and could be exploited as a therapeutic agent for the treatment of diabetic ulcers., This work was supported by the RETICS Program (RD16/0011/0004 and RD16/0011/0005) of the Instituto de Salud Carlos III, co-funded by FEDER 'una manera de hacer Europa,' and by PROJECT RESOLTEX (RTC-2015-4185-1) of the Ministerio de Economia y Competitividad through the RETOS program. It was also supported by grant ACIF/2020/352 to E.A.-P. from the Conselleria de Innovacion, Universidades, Ciencia, y Sociedad Digital and co-financed by the European Union through the Operational Program of the European Regional Development Fund (FEDER) of the Valencian Community 2014-2020, and from the Instituto de Salud Carlos III, co-funded by FEDER, to P.S (PI19/00245) and B.P. (PI19/00501).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Consensus document on frailty: conceptualization, detection, multidisciplinary management and future roadmap

  • Álvarez Bustos, Alejandro
  • Andrés-Lacueva, Cristina
  • Ara, Ignacio
  • Arévalo, María Ángeles
  • Bolaños, Juan P.
  • Coto-Montes, Ana
  • Enríquez, José Antonio
  • Escames, Germaine
  • García García, Francisco José
  • Gómez Cabrera, Mari Carmen
  • Grau-Rivera, Oriol
  • Izquierdo Redín, Mikel
  • Martínez Velilla, Nicolás
  • Matheu, Ander
  • Menéndez Colino, Rocío
  • Muñoz Torres, Manuel
  • Nogués, Xavier
  • Oliva Moreno, Juan
  • Orts-Cortés, María Isabel
  • Párraga Martínez, Ignacio
  • Priego, Feliciano
  • Rabassa-Bonet, Montserrat
  • Rol, María Ángeles
  • Serra-Rexach, José Antonio
  • Tarazona-Santabalbina, Francisco José
  • Rodríguez Mañas, Leocadio
  • Abizanda, Pedro
  • CIBERFES Working Group
Background: The lack of a universally accepted definition, a gold-standard assessment tool, and sufficient evidence-based interventions has hindered the integration of frailty into routine clinical practice, particularly outside geriatric medicine. For clinicians, health professionals, policymakers, and aging researchers, a unified framework based on robust evidence has become essential. Objectives: To provide a consensus on relevant aspects of frailty, including definition, attributes, misunderstandings, pathophysiology, phenotypes, assessment, biomarkers, management, stigmas and future challenges, useful for epidemiological, clinical and research application across Europe. Design: Consensus document. Setting: 25 research centers on frailty and healthy aging. Measurements: Relevant aspects on frailty. Results: In this document we present a consensus regarding what frailty is, what frailty is not, what is aging, which are the most common misunderstandings related to frailty, which is the pathophysiology and which are the biomarkers of frailty, how should frailty be assessed and who should assess frailty, how should frailty be managed, the presence or absence of frailty subphenotypes or subtypes, how is the stigma of been considered frail, which are the gender considerations, and which are the current challenges and future directions. We support that frailty is the expression of an age-associated clinical phenotypic syndrome driven by the biology of aging, life-course environmental exposures, and disease burden. Its physiological basis lies in a heterogeneous decline of functional reserve across organ systems, accompanied by impaired homeostasis and reduced capacity to respond to stressors, ultimately predisposing to adverse health outcomes, mainly disability. Conclusions: We present a consensus document on frailty, useful for epidemiological, clinical and research application across Europe., The present study received funding from the projects CB16/10/00408, CB16/10/00269, CB16/10/00477, CB16/10/00383, CB16/10/00282, CB16/10/00289, CB16/10/00238, CB16/10/00456, CB16/10/00435, CB16/10/00417, CB16/10/00315, CB16/10/00496, CB16/10/00468, CB16/10/00475, CB16/10/00245, CB23/10/00037, CB16/10/00501, CB16/10/00464, CB16/10/00239, CB16/10/00314, Instituto de Salud Carlos III, Madrid, Spain.
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

Patients Infected with HIV in the Intensive Care Unit (2005 Through 2010): Significant Role of Chronic Hepatitis C and Severe Sepsis

  • Medrano Laporte, José
  • Álvaro Meca, Luis Alejandro
  • Boyer, Alexandre
  • Jiménez Sousa, María A.
  • Resino, Salvador
Introduction: The combination antiretroviral therapy (cART) has led to decreased opportunistic infections and hospital admissions in human immunodeficiency virus (HIV)-infected patients, but the intensive care unit (ICU) admission rate remains constant (or even increased in some instances) during the cART era. Hepatitis C virus (HCV) infection is associated with an increased risk for hospital admission and/or mortality (particularly those related to severe liver disease) compared with the general population. The aim of this study was to assess the mortality among HIV-infected patients in ICU, and to evaluate the impact of HIV/HCV coinfection and severe sepsis on ICU mortality. Methods: We carried out a retrospective study based on patients admitted to ICU who were recorded in the Minimum Basic Data Set (2005 through 2010) in Spain. HIV-infected patients (All-HIV-group (n = 1,891)) were divided into two groups: HIV-monoinfected patients (HIV group (n = 1,191)) and HIV/HCV-coinfected patients (HIV/HCV group (n = 700)). A control group (HIV(-)/HCV(-)) was also included (n = 7,496). Results: All-HIV group had higher frequencies of severe sepsis (57.7% versus 39.4%; P < 0.001) than did the control group. Overall, ICU mortality in patients with severe sepsis was much more frequent than that in patients without severe sepsis (other causes) at days 30 and 90 in HIV-infected patients and the control group (P < 0.001). Moreover, the all-HIV group in the presence or absence of severe sepsis had a higher percentage of death than did the control group at days 7 (P < 0.001), 30 (P < 0.001) and 90 (P < 0.001). Besides, the HIV/HCV group had a higher percentage of death, both in patients with severe sepsis and in patients without severe sepsis compared with the HIV group at days 7 (P < 0.001) and 30 (P < 0.001), whereas no differences were found at day 90. In a bayesian competing-risk model, the HIV/HCV group had a higher mortality risk (adjusted hazard ratio (aHR) = 1.44 (95% Cl = 1.30 to 1.59) and aHR = 1.57 (95% CI = 1.38 to 1.78) for patients with and without severe sepsis, respectively). Conclusions: HIV infection was related to a higher frequency of severe sepsis and death among patients admitted to the ICU. Besides, HIV/HCV coinfection contributed to an increased risk of death in both the presence and the absence of severe sepsis., This research has been supported by Instituto de Salud Carlos III (grant numbers PI11/00245 to SR and PI12/00019 to AAM). MAJS is supported by a contract of Instituto de Salud Carlos III (grant number CD13/00013).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Consensus document on frailty: conceptualization, detection, multidisciplinary management and future roadmap

  • Álvarez-Bustos, Alejandro
  • Andrés-Lacueva, Cristina
  • Ara, Ignacio
  • Arévalo, María Ángeles
  • Bolaños, Juan P.
  • Coto, Ana
  • Enríquez, José Antonio
  • Escames, Germaine
  • García-García, Francisco José
  • Gómez-Cabrera, Mari Carmen
  • Grau, Oriol
  • Izquierdo, Mikel
  • Martínez Velilla, Nicolás
  • Matheu, Ander
  • Menéndez Colino, Rocío
  • Muñoz Torres, Manuel
  • Nogués, Xavier
  • Oliva, Juan
  • Orts-Cortés, María Isabel
  • Párraga Martínez, Ignacio
  • Priego, Feliciano
  • Rabassa, Montserrat
  • Rol, María Ángeles
  • Serra-Rexach, José Antonio
  • Tarazona-Santabalbina, Francisco José
  • Rodríguez-Mañas, Leocadio
  • Abizanda, Pedro
The lack of a universally accepted definition, a gold-standard assessment tool, and sufficient evidence-based interventions has hindered the integration of frailty into routine clinical practice, particularly outside geriatric medicine. For clinicians, health professionals, policymakers, and aging researchers, a unified framework based on robust evidence has become essential., The present study received funding from the projects CB16/10/00408, CB16/10/00269, CB16/10/00477, CB16/10/00383, CB16/10/00282, CB16/10/00289, CB16/10/00238, CB16/10/00456, CB16/10/00435, CB16/10/00417, CB16/10/00315, CB16/10/00496, CB16/10/00468, CB16/10/00475, CB16/10/00245, CB23/10/00037, CB16/10/00501, CB16/10/00464, CB16/10/00239, CB16/10/00314, Instituto de Salud Carlos III, Madrid, Spain., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

SNPs in bone-related miRNAs are associated with the osteoporotic phenotype

  • De-Ugarte, L.
  • Caro-Molina, E.
  • Rodríguez-Sanz, M.
  • Garciá-Pérez, M. A.
  • Olmos, J. M.
  • Sosa-Henríquez, M.
  • Pérez-Cano, R.
  • Gómez-Alonso, C.
  • Del Rio, L.
  • Mateo-Agudo, J.
  • Blázquez-Cabrera, J. A.
  • González-Maciás, J.
  • Pino-Montes, J.
  • Munõz-Torres, M.
  • DIaz-Curiel, M.
  • Malouf, J.
  • Cano, A.
  • Pérez-Castrillon, J. L.
  • Nogues, X.
  • Garcia-Giralt, N.
  • DIez-Perez, A.
Biogenesis and function of microRNAs can be influenced by genetic variants in the pri-miRNA sequences leading to phenotypic variability. This study aims to identify single nucleotide polymorphisms (SNPs) affecting the expression levels of bone-related mature microRNAs and thus, triggering an osteoporotic phenotype. An association analysis of SNPs located in pri-miRNA sequences with bone mineral density (BMD) was performed in the OSTEOMED2 cohort (n = 2183). Functional studies were performed for assessing the role of BMD-associated miRNAs in bone cells. Two SNPs, rs6430498 in the miR-3679 and rs12512664 in the miR-4274, were significantly associated with femoral neck BMD. Further, we measured these BMD-associated microRNAs in trabecular bone from osteoporotic hip fractures comparing to non-osteoporotic bone by qPCR. Both microRNAs were found overexpressed in fractured bone. Increased matrix mineralization was observed after miR-3679-3p inhibition in human osteoblastic cells. Finally, genotypes of rs6430498 and rs12512664 were correlated with expression levels of miR-3679 and miR-4274, respectively, in osteoblasts. In both cases, the allele that generated higher microRNA expression levels was associated with lower BMD values. In conclusion, two osteoblast-expressed microRNAs, miR-3679 and miR-4274, were associated with BMD; their overexpression could contribute to the osteoporotic phenotype. These findings open new areas for the study of bone disorders.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

SR-B1, a Key Receptor Involved in the Progression of Cardiovascular Disease: A Perspective from Mice and Human Genetic Studies

  • Gracia Rubio, Irene
  • Martín, C.
  • Civeira, Fernando
  • Cenarro, Ana
High plasma level of low-density lipoprotein (LDL) is the main driver of the initiation and progression of cardiovascular disease (CVD). Nevertheless, high-density lipoprotein (HDL) is con-sidered an anti-atherogenic lipoprotein due to its role in reverse cholesterol transport and its ability to receive cholesterol that effluxes from macrophages in the artery wall. The scavenger receptor B class type 1 (SR-B1) was identified as the high-affinity HDL receptor, which facilitates the selective uptake of cholesterol ester (CE) into the liver via HDL and is also implicated in the plasma clearance of LDL, very low-density lipoprotein (VLDL) and lipoprotein(a) (Lp(a)). Thus, SR-B1 is a multifunc-tional receptor that plays a main role in the metabolism of different lipoproteins. The aim of this review is to highlight the association between SR-B1 and CVD risk through mice and human genetic studies.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Low Zinc Levels at Admission Associates with Poor Clinical Outcomes in SARS-CoV-2 Infection

  • Vogel-González, Marina
  • Herrera-Fernández, Víctor
  • Pérez-Vilaró, Gemma
  • Chillon Rodriguez, Miguel
  • Nogués, Xavier
  • Talló-Parra, Marc
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Resultats clínics; Zinc, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Resultados clínicos; Zinc, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Clinical outcomes; Zinc, Background: Zinc is an essential micronutrient that impacts host–pathogen interplay at infection. Zinc balances immune responses, and also has a proven direct antiviral action against some viruses. Importantly, zinc deficiency (ZD) is a common condition in elderly and individuals with chronic diseases, two groups with an increased risk for severe severe coronavirus disease 2019 (COVID-19) outcomes. We hypothesize that serum zinc content (SZC) influences COVID-19 disease progression, and thus might represent a useful biomarker. Methods: We ran an observational cohort study with 249 COVID-19 patients admitted in Hospital del Mar. We have studied COVID-19 severity and progression attending to SZC at admission. In parallel, we have studied severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) replication in the Vero E6 cell line modifying zinc concentrations. Findings: Our study demonstrates a correlation between serum zinc levels and COVID-19 outcome. Serum zinc levels lower than 50 µg/dL at admission correlated with worse clinical presentation, longer time to reach stability, and higher mortality. Our in vitro results indicate that low zinc levels favor viral expansion in SARS-CoV-2 infected cells. Interpretation: Low SZC is a risk factor that determines COVID-19 outcome. We encourage performing randomized clinical trials to study zinc supplementation as potential prophylaxis and treatment with people at risk of zinc deficiency., This work was supported by the Spanish Ministry of Science and Innovation, through grants PID2019-106755RB-I00/AEI/10.13039/501100011033 to R.V. and PID2019-106959RB-I00/AEI/10.13039/501100011033 to J.D.; an institutional “Maria de Maeztu” Programme for Units of Excellence in R&D (CEX2018-000792-M) to R.V. and J.D.; and by the 2017 SGR 909 grant from the Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement of the Generalitat de Catalunya to J.D. R.G.-F. received support and funding from Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (grant number CB16/10/00245), FEDER funds, and the FIS Project from Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación (grant number (PI19/00019)).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Low Zinc Levels at Admission Associates with Poor Clinical Outcomes in SARS-CoV-2 Infection

  • Vogel-González, Marina
  • Talló-Parra, Marc
  • Herrera-Fernández, Víctor
  • Pérez-Vilaró, Gemma
  • Chillón Rodríguez, Miguel|||0000-0003-0840-2111
  • Nogués Solán, Xavier|||0000-0002-5537-1859
  • Gómez-Zorrilla, Silvia|||0000-0002-5987-068X
  • López Montesinos, Inmaculada|||0000-0002-2675-4412
  • Arnau-Barrés, Isabel
  • Sorlí, Luisa|||0000-0001-9562-514X
  • Horcajada, Juan Pablo|||0000-0001-9873-5459
  • Garcia-Giralt, Natalia|||0000-0001-6507-0147
  • Pascual, Julio|||0000-0002-4735-7838
  • Díez, Juana|||0000-0002-9013-0751
  • Vicente, Rubén|||0000-0003-0401-4808
  • Güerri-Fernández, Robert|||0000-0002-9794-9161
Background: Zinc is an essential micronutrient that impacts host-pathogen interplay at infection. Zinc balances immune responses, and also has a proven direct antiviral action against some viruses. Importantly, zinc deficiency (ZD) is a common condition in elderly and individuals with chronic diseases, two groups with an increased risk for severe severe coronavirus disease 2019 (COVID-19) outcomes. We hypothesize that serum zinc content (SZC) influences COVID-19 disease progression, and thus might represent a useful biomarker. Methods: We ran an observational cohort study with 249 COVID-19 patients admitted in Hospital del Mar. We have studied COVID-19 severity and progression attending to SZC at admission. In parallel, we have studied severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) replication in the Vero E6 cell line modifying zinc concentrations. Findings: Our study demonstrates a correlation between serum zinc levels and COVID-19 outcome. Serum zinc levels lower than 50 µg/dL at admission correlated with worse clinical presentation, longer time to reach stability, and higher mortality. Our in vitro results indicate that low zinc levels favor viral expansion in SARS-CoV-2 infected cells. Interpretation: Low SZC is a risk factor that determines COVID-19 outcome. We encourage performing randomized clinical trials to study zinc supplementation as potential prophylaxis and treatment with people at risk of zinc deficiency.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

SNPs in bone-related miRNAs are associated with the osteoporotic phenotype

  • De-Ugarte, Laura
  • Caro-Molina, Enrique
  • Rodríguez-Sanz, Maria
  • García-Pérez, Miguel Angel
  • Olmos, José M.
  • Sosa-Henríquez, Manuel
  • Pérez-Cano, Ramón
  • Gómez-Alonso, Carlos|||0000-0003-1424-8659
  • Del Rio, Luis|||0000-0003-0720-0673
  • Mateo-Agudo, Jesús
  • Blázquez-Cabrera, José Antonio
  • González-Macías, Jesús
  • Pino-Montes, Javier del
  • Muñoz-Torres, Manuel
  • Diaz-Curiel, Manuel|||0000-0002-7762-9398
  • Malouf Sierra, Jorge|||0000-0001-5185-520X
  • Cano, Antonio
  • Pérez-Castrillon, José Luis
  • Nogués Solán, Xavier|||0000-0002-5537-1859
  • Garcia-Giralt, Natalia|||0000-0001-6507-0147
  • Díez Pérez, Adolfo|||0000-0001-8162-0209
Biogenesis and function of microRNAs can be influenced by genetic variants in the pri-miRNA sequences leading to phenotypic variability. This study aims to identify single nucleotide polymorphisms (SNPs) affecting the expression levels of bone-related mature microRNAs and thus, triggering an osteoporotic phenotype. An association analysis of SNPs located in pri-miRNA sequences with bone mineral density (BMD) was performed in the OSTEOMED2 cohort (n = 2183). Functional studies were performed for assessing the role of BMD-associated miRNAs in bone cells. Two SNPs, rs6430498 in the miR-3679 and rs12512664 in the miR-4274, were significantly associated with femoral neck BMD. Further, we measured these BMD-associated microRNAs in trabecular bone from osteoporotic hip fractures comparing to non-osteoporotic bone by qPCR. Both microRNAs were found overexpressed in fractured bone. Increased matrix mineralization was observed after miR-3679-3p inhibition in human osteoblastic cells. Finally, genotypes of rs6430498 and rs12512664 were correlated with expression levels of miR-3679 and miR-4274, respectively, in osteoblasts. In both cases, the allele that generated higher microRNA expression levels was associated with lower BMD values. In conclusion, two osteoblast-expressed microRNAs, miR-3679 and miR-4274, were associated with BMD; their overexpression could contribute to the osteoporotic phenotype. These findings open new areas for the study of bone disorders.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Severe hypoalbuminemia at admission is strongly associated with worse prognosis in older adults with sars-cov-2 infection

  • Arnau-Barrés, Isabel
  • Pascual-Dapena, Ana
  • López Montesinos, Inmaculada|||0000-0002-2675-4412
  • Gómez-Zorrilla, Silvia|||0000-0002-5987-068X
  • Sorlí, Luisa|||0000-0001-9562-514X
  • Herrero-Torrus, Marta
  • Nogués Solán, Xavier|||0000-0002-5537-1859
  • Navarro-Valls, Claudia
  • Ibarra, Beatriz
  • Canchucaja, Lizzeth
  • Da Costa, Elizabeth
  • Blasco-Hernando, Fabiola
  • Cruz, Juany
  • Vázquez Ibar, Olga|||0000-0001-8260-4585
  • Miralles Basseda, Ramon|||0000-0002-7770-7819
  • Garcia-Giralt, Natalia|||0000-0001-6507-0147
  • Güerri-Fernández, Robert|||0000-0002-9794-9161
Serum albumin levels have been associated with prognosis in several conditions among older adults. The aim of this study is to assess the prognostic value in mortality of serum albumin in older adults with SARS-CoV-2 infection. Methods. Cohort observational study with consecu-tive older-adults (≥65 years old), with confirmed SARS-CoV-2 infection admitted to a university hospital between March-May 2020. A logistic regression model was fitted to assess the impact of albumin levels on in-hospital mortality adjusted by potential confounders. Results. Among a total of 840 patients admitted to the hospital, 405 (48%) were older adults with a total of 92 deaths (23%) among them. Those who died were older, had more comorbidities, higher inflammation status and lower levels of serum albumin at admission [3.10 g/dL (0.51) vs. 3.45 g/dL (0.45); p < 0.01. Serum albumin levels at admission were negatively correlated with inflammatory markers such as C-Reactive protein (Pearson Coeff -0.4634; p < 0.001) or IL-6 (Pearson's Coeff -0.244; p = 0.006) at admission but also to other clinical outcomes such time to clinical stability (Pearson's Coeff -0.259; p < 0.001). Severe hypoalbuminemia associated with increased risk of mortality was defined as ≤3 g/dL at admission according to the AUC/ROC analysis (0.72 95%CI 0.63-0.81) In a multivariate logistic regression model adjusting by age, inflammation, comorbidities and severity at admission severe hypoalbuminemia was a strong predictor of in-hospital mortality (OR 2.18 95% CI 1.03-4.62; p = 0.039). Conclusion. Severe hypoalbuminemia with ≤3 g/dL is an independent risk factor for mortality among older adults with SARS-CoV-2 infection. There is a consistent correlation between albumin levels and inflammatory biomarkers. Further studies are needed to determine whether the supplementation of albumin as coadjuvant treatment will have a positive impact on the prognosis of this infection.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Prevalence and prognostic value of myocardial injury in the initial presentation of sars-cov-2 infection among older adults

  • Arnau-Barrés, Isabel
  • Pascual-Dapena, Ana
  • López Montesinos, Inmaculada|||0000-0002-2675-4412
  • Gómez-Zorrilla, Silvia|||0000-0002-5987-068X
  • Sorlí, Luisa|||0000-0001-9562-514X
  • Herrero-Torrus, Marta
  • Nogués Solán, Xavier|||0000-0002-5537-1859
  • Montero, Mila
  • Vázquez Ibar, Olga|||0000-0001-8260-4585
  • Garcia-Giralt, Natalia|||0000-0001-6507-0147
  • Miralles Basseda, Ramon|||0000-0002-7770-7819
  • Güerri-Fernández, Robert|||0000-0002-9794-9161
Myocardial involvement during SARS-CoV-2 infection has been reported in many prior publications. We aim to study the prevalence and the clinical implications of acute myocardial injury (MIN) during SARS-CoV-2 infection, particularly in older patients. The method includes a longitudinal observational study with all consecutive adult patients admitted to a COVID-19 unit between March-April 2020. Those aged ≥65 were considered as older adult group. MIN was defined as at least 1 high-sensitive troponin (hs-TnT) concentration above the 99th percentile upper reference limit with different sex-cutoff. Results. Among the 634 patients admitted during the period of observation, 365 (58%) had evidence of MIN, and, of them, 224 (61%) were older adults. Among older adults, MIN was associated with longer time to recovery compared to those without MIN (13 days (IQR 6-21) versus 9 days (IQR 5-17); p < 0.001, respectively. In-hospital mortality was significantly higher in older adults with MIN at admission versus those without it (71 (31%) versus 11 (12%); p < 0.001). In a logistic regression model adjusting by age, sex, severity, and Charlson Comorbidity Index, the OR for in-hospital mortality was 2.1 (95% CI: 1.02-4.42; p = 0.043) among those older adults with MIN at admission. Older adults with acute myocardial injury had greater time to clinical recovery, as well as higher odds of in-hospital mortality.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Individuals With Higher CD4/CD8 Ratio Exhibit Increased Risk of Acute Respiratory Distress Syndrome and In-Hospital Mortality During Acute SARS-CoV-2 Infection

  • Pascual-Dapena, Ana
  • Chillaron, Juan Jose|||0000-0002-8096-1703
  • Llauradó, Gemma|||0000-0002-3237-6366
  • Arnau-Barrés, Isabel
  • Flores, Juana María
  • Lopez-Montesinos, Inmaculada
  • Sorlí, Luisa|||0000-0001-9562-514X
  • Luis Martínez-Pérez, Juan
  • Gómez-Zorrilla, Silvia|||0000-0002-5987-068X
  • Du, Juan
  • Garcia-Giralt, Natalia|||0000-0001-6507-0147
  • Güerri-Fernández, Robert|||0000-0002-9794-9161
CD4/CD8 ratio has been used as a quantitative prognostic risk factor in patients with viral infections. This study aims to assess the association between in-hospital mortality and at admission CD4/CD8 ratio among individuals with acute SARS-CoV-2 infection. This is a longitudinal cohort study with data of all consecutive patients admitted to the COVID-19 unit at Hospital del Mar, Barcelona, Spain for ≥48 h between March to May 2020. The CD4+ CD8+ T-cell subset differentiation was assessed by flow cytometry at admission as well as a complete blood test. Patients were classified according to CD4/CD8 ratio tertiles. The primary outcome was in-hospital mortality and the secondary outcome was acute respiratory distress (ARDS). A total of 338 patients were included in the cohort. A high CD4/CD8 ratio (third tertile) was associated with a higher in-hospital mortality [adjusted Cox model hazard ratio (HR) 4.68 (95%CI 1.56-14.04, p = 0.006), reference: second tertile HR 1]. Similarly, a high CD4/CD8 ratio (third tertile) was associated with a higher incidence of ARDS [adjusted logistic regression model OR 1.97 (95%CI 1.11-3.55, p = 0.022) reference: second tertile HR 1]. There was a trend of higher in-hospital mortality and incidence of ARDS in patients within the first tertile of CD4/CD8 ratio compared with the second one, but the difference was not significant. No associations were found with total lymphocyte count or inflammatory parameters, including D-dimer. CD4/CD8 ratio is a prognostic factor for the severity of COVID-19, reflecting the negative impact on prognosis of those individuals whose immune response has abnormal CD8+ T-cell expansion during the early response to the infection.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Pan-pox-specific T-cell responses in HIV-1-infected individuals after JYNNEOS vaccination

  • Sisteré-Oró, Marta|||0000-0003-0214-6348
  • Du, Juan
  • Wortmann, Diana D.J.
  • Filippi, Marina D.
  • Cañas-Ruano, Esperanza|||0000-0002-4651-7545
  • Arrieta-Aldea, Itziar
  • Marcos-Blanco, Agustín
  • Castells, Xavier|||0000-0002-2528-0382
  • Grau, Santiago|||0000-0002-8428-1836
  • Garcia-Giralt, Natalia|||0000-0001-6507-0147
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Boreika, Rytis|||0000-0001-6720-1577
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Güerri-Fernández, Robert|||0000-0002-9794-9161
  • Meyerhans, Andreas|||0000-0003-0620-5317
People living with human immunodeficiency virus (HIV) are the individuals most affected by the current Monkeypox virus outbreak that was first announced in May 2022. Here we report Pan-pox-specific T-cell responses in a cohort of HIV-1-infected individuals after receiving the nonreplicative, attenuated smallpox vaccine JYNNEOS from Bavarian Nordic. Intradermal (i.d.) and subcutaneous (s.c.) vaccination was safe without major side effects. Dose-sparing i.d. vaccination was superior to s.c. vaccination and promoted T-cell polyfunctionality, and the expression of the gut-homing marker α4β7 integrin on lymphocytes. HIV-1-infected individuals with CD4 T-cell counts ≤500/mm blood required at least a booster vaccination to exhibit efficient virus-specific T-cell responses. The magnitude of the Th1 response after this booster directly correlated with the CD4 T-cell count of the vaccinees. Further studies with a larger number of participants are warranted to confirm and expand our observations.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Low Zinc Levels at Admission Associates with Poor Clinical Outcomes in SARS-CoV-2 Infection

  • Vogel-González, Marina
  • Herrera-Fernández, Víctor
  • Pérez-Vilaró, Gemma
  • Chillon Rodriguez, Miguel
  • Nogués, Xavier
  • Talló-Parra, Marc
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Resultats clínics; Zinc, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Resultados clínicos; Zinc, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Clinical outcomes; Zinc, Background: Zinc is an essential micronutrient that impacts host–pathogen interplay at infection. Zinc balances immune responses, and also has a proven direct antiviral action against some viruses. Importantly, zinc deficiency (ZD) is a common condition in elderly and individuals with chronic diseases, two groups with an increased risk for severe severe coronavirus disease 2019 (COVID-19) outcomes. We hypothesize that serum zinc content (SZC) influences COVID-19 disease progression, and thus might represent a useful biomarker. Methods: We ran an observational cohort study with 249 COVID-19 patients admitted in Hospital del Mar. We have studied COVID-19 severity and progression attending to SZC at admission. In parallel, we have studied severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) replication in the Vero E6 cell line modifying zinc concentrations. Findings: Our study demonstrates a correlation between serum zinc levels and COVID-19 outcome. Serum zinc levels lower than 50 µg/dL at admission correlated with worse clinical presentation, longer time to reach stability, and higher mortality. Our in vitro results indicate that low zinc levels favor viral expansion in SARS-CoV-2 infected cells. Interpretation: Low SZC is a risk factor that determines COVID-19 outcome. We encourage performing randomized clinical trials to study zinc supplementation as potential prophylaxis and treatment with people at risk of zinc deficiency., This work was supported by the Spanish Ministry of Science and Innovation, through grants PID2019-106755RB-I00/AEI/10.13039/501100011033 to R.V. and PID2019-106959RB-I00/AEI/10.13039/501100011033 to J.D.; an institutional “Maria de Maeztu” Programme for Units of Excellence in R&D (CEX2018-000792-M) to R.V. and J.D.; and by the 2017 SGR 909 grant from the Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement of the Generalitat de Catalunya to J.D. R.G.-F. received support and funding from Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES) (grant number CB16/10/00245), FEDER funds, and the FIS Project from Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación (grant number (PI19/00019)).